FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597968140> ?p ?o ?g. }

• W2597968140 endingPage "5193" @default.
• W2597968140 startingPage "5193" @default.
• W2597968140 abstract "Abstract Introduction: Prognosis of acute lymphoblastic leukemia (ALL) in adults remains dismal. Recent advances have consisted of targeted therapies with monoclonal antibodies and chimeric antigen receptor (CAR) T lymphocytes (anti-CD19 CAR T cells), showing very encouraging results. However, relapse still occur after this new therapeutics and increasing the armamentarium for ALL is still required. Her2 is expressed in above one third of adult B-ALL (Chevallier,Haematologica 2009). The anti-HER2 antibodytrastuzumab has been tested prospectively in such patients, showing a low efficacy (Chevallier, Blood 2012).The present work was designed to compare, in vitro, thelysis sensibility of B-ALL HER2+ mediated by two mechanisms of HER2 recognition based on antibody (Ab) specificity: firstly, when the anti-HER2 monoclonalAbtrastuzumab bridges target cells and cytotoxic lymphocytes armed with a Fc receptor (antibodydependant cellular cytotoxicity, ADCC) andsecondly, when HER2-positive target cells are directly recognized by cytotoxic lymphocytes armed with a chimeric antigen receptor (anti-HER2 CAR). Methods: Frozen samples from 7 HER2+ B-ALL adults were available, including onesample expressing also CD20. Characteristics of Patients and controls are presented in Table 1. Three human breast-cancer cell lines (BCCL) expressing different validated (HercepTest, Dako) levels of HER2 (BT474 (HER2 3+), MCF-7 (HER2 0-/1+) and MDA-MB-231 (HER2 0-/1+) were used as positive control. Leukemic HER2-negative B-ALL cells from two patients were used as negative control, including one patient with CD20+ expression. The level of HER2 expression by HER2+ B-ALL was determined by fluorescence-activated cell sorter (FACS) and compared to the HER2 expressing BCCL.Cytotoxic activity was assessed at a 30-to-1 effector-to-target ratio in a 4 hours 51Cr-release assay.We used the same cytotoxic effector lymphocytes (the human NK cell line NK-92), armed with eitheraFcγRIIIa/FcεRIγ receptor (referred to as NK-92CD16) or with an anti-HER2/FcεRIγ CAR receptor (referred to as NK-92CAR) as previously described (Clémenceau, JImmunol Research 2015). For ADCC/CAR assays, target cells were pre-incubated withtrastuzumab and /or rituximab at 10µg/ml each. The study was approved by our local review board and twoalivepatients gave informed consent. Results: The level of HER2 expression by HER2+ B-ALL (n=7) was highly variable with a mean relative fluorescence intensity ratio (RFI) of 13 (range 5 to 30). According to the HercepTestranking used for BCCL lines (see above) all B-ALL would be classified as HER2 0-/1+. In vitro HER2+ BCCL were efficiently lysed by anti-HER2 NK-92CAR in this 4 hours 51Cr-release assay and this direct pathway of killing by CAR was always more efficient than the indirect pathway mediated by ADCC. In addition, thelysis level was correlated to HER2 level expression. Trastuzumabalone has no effect on the spontaneous 51Cr-release of B-ALL cells (not shown). Anti-HER2 CAR mediatedlysis was observed for 5 out of 6 HER2+ B-ALL cells (83%, 1 case (#5) non interpretable). Although lysis levels were low, they werespecificsince the CAR mediatedlysis was inhibited when the B-ALL were pre-incubated with 10 µg/mltrastuzumab (not shown). In contrast, for these 5 HER2+ B-ALL, no anti-HER2 ADCClysis was observed. These results confirmed that in these experimental conditions, HER2 targeting by CAR is more efficient than by ADCC. For the two HER2- B-ALL, no ADCC or CARlysis were observed. Finally, for the two B-ALL expressing CD20, anti-CD20 ADCClysiscan be observed demonstrating that B-ALL cells are not intrinsically resistant to ADCCcytoxicity. Regarding the unique case of B-ALL expressing both CD20/HER2 antigens, only anti-CD20 ADCClysiswas observed. Results are presented in Table 2. Conclusion: Together, these preliminary results suggest that for the CD20-negative and HER2-positive B-ALLs, one cannot rely on ADCC as a mechanism of target celllysis, while the interest of an anti-HER2-CAR approach deserve further studies to better correlate the level of HER2 expression and the sensitivity tolysisby HER2-specific CAR. Disclosures No relevant conflicts of interest to declare." @default.
• W2597968140 created "2017-04-07" @default.
• W2597968140 creator A5007731800 @default.
• W2597968140 creator A5023982618 @default.
• W2597968140 creator A5035126631 @default.
• W2597968140 creator A5036207495 @default.
• W2597968140 creator A5044090334 @default.
• W2597968140 creator A5058532201 @default.
• W2597968140 creator A5061595252 @default.
• W2597968140 creator A5081625864 @default.
• W2597968140 creator A5084200733 @default.
• W2597968140 date "2016-12-02" @default.
• W2597968140 modified "2023-10-17" @default.
• W2597968140 title "In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)" @default.
• W2597968140 doi "https://doi.org/10.1182/blood.v128.22.5193.5193" @default.
• W2597968140 hasPublicationYear "2016" @default.
• W2597968140 type Work @default.
• W2597968140 sameAs 2597968140 @default.
• W2597968140 citedByCount "0" @default.
• W2597968140 crossrefType "journal-article" @default.
• W2597968140 hasAuthorship W2597968140A5007731800 @default.
• W2597968140 hasAuthorship W2597968140A5023982618 @default.
• W2597968140 hasAuthorship W2597968140A5035126631 @default.
• W2597968140 hasAuthorship W2597968140A5036207495 @default.
• W2597968140 hasAuthorship W2597968140A5044090334 @default.
• W2597968140 hasAuthorship W2597968140A5058532201 @default.
• W2597968140 hasAuthorship W2597968140A5061595252 @default.
• W2597968140 hasAuthorship W2597968140A5081625864 @default.
• W2597968140 hasAuthorship W2597968140A5084200733 @default.
• W2597968140 hasConcept C147483822 @default.
• W2597968140 hasConcept C154317977 @default.
• W2597968140 hasConcept C159654299 @default.
• W2597968140 hasConcept C18031839 @default.
• W2597968140 hasConcept C202751555 @default.
• W2597968140 hasConcept C203014093 @default.
• W2597968140 hasConcept C2777701055 @default.
• W2597968140 hasConcept C3875195 @default.
• W2597968140 hasConcept C40677261 @default.
• W2597968140 hasConcept C502942594 @default.
• W2597968140 hasConcept C542903549 @default.
• W2597968140 hasConcept C55493867 @default.
• W2597968140 hasConcept C71924100 @default.
• W2597968140 hasConcept C86803240 @default.
• W2597968140 hasConcept C8891405 @default.
• W2597968140 hasConceptScore W2597968140C147483822 @default.
• W2597968140 hasConceptScore W2597968140C154317977 @default.
• W2597968140 hasConceptScore W2597968140C159654299 @default.
• W2597968140 hasConceptScore W2597968140C18031839 @default.
• W2597968140 hasConceptScore W2597968140C202751555 @default.
• W2597968140 hasConceptScore W2597968140C203014093 @default.
• W2597968140 hasConceptScore W2597968140C2777701055 @default.
• W2597968140 hasConceptScore W2597968140C3875195 @default.
• W2597968140 hasConceptScore W2597968140C40677261 @default.
• W2597968140 hasConceptScore W2597968140C502942594 @default.
• W2597968140 hasConceptScore W2597968140C542903549 @default.
• W2597968140 hasConceptScore W2597968140C55493867 @default.
• W2597968140 hasConceptScore W2597968140C71924100 @default.
• W2597968140 hasConceptScore W2597968140C86803240 @default.
• W2597968140 hasConceptScore W2597968140C8891405 @default.
• W2597968140 hasIssue "22" @default.
• W2597968140 hasLocation W25979681401 @default.
• W2597968140 hasOpenAccess W2597968140 @default.
• W2597968140 hasPrimaryLocation W25979681401 @default.
• W2597968140 hasRelatedWork W1602847563 @default.
• W2597968140 hasRelatedWork W1985837387 @default.
• W2597968140 hasRelatedWork W1997716688 @default.
• W2597968140 hasRelatedWork W2000365588 @default.
• W2597968140 hasRelatedWork W2038126255 @default.
• W2597968140 hasRelatedWork W2064089409 @default.
• W2597968140 hasRelatedWork W2115013237 @default.
• W2597968140 hasRelatedWork W2476973230 @default.
• W2597968140 hasRelatedWork W3193741685 @default.
• W2597968140 hasRelatedWork W339756260 @default.
• W2597968140 hasVolume "128" @default.
• W2597968140 isParatext "false" @default.
• W2597968140 isRetracted "false" @default.
• W2597968140 magId "2597968140" @default.
• W2597968140 workType "article" @default.